Amylyx Pharmaceuticals (AMLX) EBT Margin (2021 - 2024)
Amylyx Pharmaceuticals (AMLX) posted quarterly EBT Margin of 6003.3% for Q4 2024, up 599921.0% year-over-year from N/an in Q1 2024, and up 134.35% quarter-over-quarter from 17476.92% in Q3 2024.
Amylyx Pharmaceuticals (AMLX) EBT Margin (2021 - 2024) Analysis & Trends
Amylyx Pharmaceuticals' EBT Margin history runs 4 years deep, the most recent figure standing at 6003.3% for Q4 2024.
- In Q4 2024, EBT Margin rose 599921.0% year-over-year to 6003.3%; the TTM figure through Sep 2025 stood at 23571.86% (up 2370257.0% YoY), while the FY2024 annual figure was 345.69%, down 35942.0% from the prior year.
- EBT Margin for Q4 2024 stood at 6003.3%, up from 17476.92% in the prior quarter.
- The five-year high for EBT Margin was 6003.3% in Q4 2024, with the low at 17476.92% in Q3 2024.
- The 4-year median for EBT Margin is 133.74% (2024), against an average of 3872.44%.
- The sharpest annual moves came in 2023 and 2024: EBT Margin surged 1563950 bps in 2023, then slumped 1749875 bps in 2024.
- Amylyx Pharmaceuticals' EBT Margin stood at 8120.0% in 2021, then soared by 98 bps to 197.52% in 2022, then jumped by 102 bps to 4.1% in 2023, then soared by 146467 bps to 6003.3% in 2024.
- Business Quant data shows AMLX's EBT Margin at 6003.3% in Q4 2024, 17476.92% in Q3 2024, and 7106.55% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | -10.99% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 35.09% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 13.34% |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 47.58% |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | -1.70% |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 16.91% |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 4.09% |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Amylyx Pharmaceuticals | 4.36 Bn | 4.36 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 6,003.30% |
| Sep 30, 2024 | -17,476.92% |
| Jun 30, 2024 | -7,106.55% |
| Mar 31, 2024 | -133.74% |
| Dec 31, 2023 | 4.10% |
| Sep 30, 2023 | 21.82% |
| Jun 30, 2023 | 24.44% |
| Mar 31, 2023 | 1.96% |
| Dec 31, 2022 | -197.52% |
| Sep 30, 2022 | -15,617.68% |
| Sep 30, 2021 | -8,120.00% |